<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04643769</url>
  </required_header>
  <id_info>
    <org_study_id>ORIN1001-002</org_study_id>
    <nct_id>NCT04643769</nct_id>
  </id_info>
  <brief_title>Evaluation of Oral ORIN1001 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)</brief_title>
  <official_title>Phase 1b Double-Blind, Placebo-Controlled, Ascending Dose Trial: ORIN1001 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orinove, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Orinove, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 1b trial is a double-blind, placebo-controlled, multiple ascending dose study to&#xD;
      evaluate the safety and tolerability of oral ORIN1001 at 25 mg, 50 mg or 100 mg administered&#xD;
      daily for up to 28 days in adult subjects with idiopathic pulmonary fibrosis (IPF) alone or&#xD;
      in conjunction with local Standard of Care for IPF (pirfenidone or nintedanib).&#xD;
&#xD;
      A maximum of 24 evaluable subjects will be required to complete the study. The study will&#xD;
      consist of 3 dose cohorts each enrolling a maximum of 8 subjects randomized either to the&#xD;
      active (5 subjects) group or placebo (3 subjects) group. Each subject will receive daily oral&#xD;
      doses of ORIN1001 or placebo for 28 days.&#xD;
&#xD;
      The safety and pharmacokinetic profile will be evaluated in this study and will include&#xD;
      cardiovascular and pulmonary endpoints.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase 1b trial is a double-blind, placebo-controlled, multiple ascending dose study to&#xD;
      evaluate the safety and tolerability of oral ORIN1001 at 25 mg, 50 mg or 100 mg administered&#xD;
      daily for up to 28 days in adult subjects with idiopathic pulmonary fibrosis (IPF) alone or&#xD;
      in conjunction with local standard of care (SOC) for IPF (i.e., pirfenidone or nintedanib).&#xD;
&#xD;
      Approximately 24 evaluable subjects will be required for this study. Eligible subjects will&#xD;
      be followed for safety through the dose-limiting toxicity (DLT) evaluation period, defined as&#xD;
      28 days after the first dose of ORIN1001.&#xD;
&#xD;
      In the absence of intolerable toxicity, doses will be escalated sequentially with 8 evaluable&#xD;
      subjects receiving a maximum of 28 days of ORIN1001 in once-daily doses of 25 mg (Cohort 1),&#xD;
      50 mg (Cohort 2), or 100 mg (Cohort 3) versus matched placebo. Subjects will be stratified&#xD;
      based on local SOC for IPF, defined as the stable daily dose of pirfenidone or nintedanib (or&#xD;
      neither) received for at least 8 weeks prior to signing the Informed Consent Form (ICF).&#xD;
      ORIN1001 or matched placebo will be administered daily until Day 28, unacceptable toxicity,&#xD;
      withdrawal for another reason or study termination.&#xD;
&#xD;
      Safety Endpoints will be evaluated and will include adverse events (AEs), serious adverse&#xD;
      events (SAEs), and changes in clinical laboratory evaluations as compared to baseline. Safety&#xD;
      variables include but are not limited to: vital signs (blood pressure [BP], heart rate [HR],&#xD;
      respiratory rate [RR]) and temperature; twelve-lead ECG; clinical laboratory tests&#xD;
      (hematology, coagulation profile, clinical chemistry, and urinalysis); concomitant&#xD;
      medications; physical examination; body weight; and pulmonary function tests (forced vital&#xD;
      capacity [FVC], forced expiratory volume [FEV], and diffusion capacity [DLCO]) at baseline,&#xD;
      End-of- Treatment and Follow-up Visits.&#xD;
&#xD;
      Pharmacokinetic (PK) Endpoints will be evaluated on Day 1 and Day 28 and blood collection&#xD;
      samples will be obtained from each subject. Exploratory serum biomarker endpoints will be&#xD;
      evaluated to assess lung fibrosis and inflammation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 9, 2021</start_date>
  <completion_date type="Anticipated">March 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Placebo-controlled, double blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>Up to 60 days</time_frame>
    <description>measurement of blood pressure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart Rate</measure>
    <time_frame>Up to 60 days</time_frame>
    <description>measurement of heart rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Respiratory Rate</measure>
    <time_frame>Up to 60 days</time_frame>
    <description>Measurement of respiratory rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Body Temperature</measure>
    <time_frame>Up to 60 days</time_frame>
    <description>Measurement of body temperature</description>
  </primary_outcome>
  <primary_outcome>
    <measure>12-lead ECG</measure>
    <time_frame>Up to 60 days</time_frame>
    <description>Cardiovascular evaluation to determine intervals including QTc interval</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Clinical Chemistry analysis</measure>
    <time_frame>Up to 60 days</time_frame>
    <description>ALT, albumin, ALP, AST, BUN, Ca, Cl, Cholesterol, Creatinine, CK, CA, Elastase, GGT, glucose, HDL, LDH, lipase, LDL, phosphorus, sodium, Total bilirubin, Total protein, Triglycerides, Uric acid, Lipid panel</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Whole blood Hematology analysis</measure>
    <time_frame>Up to 60 dys</time_frame>
    <description>WBC, RBC, Hb, HCT, MCV, MCH, MCHC, Neu, Lymphocytes, EOS, Bas, PLT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Whole blood Coagulation Parameters</measure>
    <time_frame>Up to 60 days</time_frame>
    <description>PT, APTT, INR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinalysis</measure>
    <time_frame>Up to 60 days</time_frame>
    <description>Bilrubin, glusoe, ketones, leukocytes, nitrite, blood, pH, specific gravity, protein, urobilinogen</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concomitant medications</measure>
    <time_frame>Up to 60 days</time_frame>
    <description>Evaluation of other medications taken currently with investigative drug</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical examination</measure>
    <time_frame>Up to 60 days</time_frame>
    <description>Medical Health examination, medical history, medicine history, reproductive history, baseline information</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Body weight</measure>
    <time_frame>Up to 60 days</time_frame>
    <description>Body weight in kg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Spirometry</measure>
    <time_frame>Up to 60 days</time_frame>
    <description>Pulmonary Function Tests: Forced vital capacity (FVC), Forced expiratory volume (FEV)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Height</measure>
    <time_frame>Up to 60 days</time_frame>
    <description>Height in cm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Body mass index (BMI)</measure>
    <time_frame>Up to 60 days</time_frame>
    <description>Calculation of BMI using weight (kg) and height (cm)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>DLCO - Assessment of diffusion capacity</measure>
    <time_frame>Up to 60 days</time_frame>
    <description>Lung test to assess diffusion capacity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood collection to measure drug concentration over time</measure>
    <time_frame>Up to 29 days</time_frame>
    <description>Blood collection for evaluation of ORIN1001 exposure. Measurements will assess half life, exposure, maximum concentration, time to maximum concentration and accumulation ratios</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Exploratory biomarkers to evaluate lung fibrosis</measure>
    <time_frame>Up to 60 days</time_frame>
    <description>Blood collection for evaluation of disease biomarker of lung fibrosis: SP-D, MMP-7 and KL6. Specific biomarker to be determined</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of Life Questionnaire</measure>
    <time_frame>Up to 60 days</time_frame>
    <description>Questionnaire to assess the quality of life during the study period</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory biomarkers to evaluate inflammation</measure>
    <time_frame>Up to 60 days</time_frame>
    <description>Blood collection for evaluation of inflammation such as cytokines TGF-B and/or IL-6</description>
  </other_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>25 mg ORIN1001 (Active)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 mg ORIN1001</description>
  </arm_group>
  <arm_group>
    <arm_group_label>50 mg ORIN1001 (active)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mg ORIN1001</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100 mg ORIN1001 (active)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg ORIN1001</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - 25 mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo comparator for ORIN1001 at 25 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - 50 mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo comparator for ORIN1001 at 50 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - 100 mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo comparator for ORIN1001 at 100 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ORIN1001</intervention_name>
    <description>Oral tablet - ORIN1001</description>
    <arm_group_label>100 mg ORIN1001 (active)</arm_group_label>
    <arm_group_label>25 mg ORIN1001 (Active)</arm_group_label>
    <arm_group_label>50 mg ORIN1001 (active)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral tablet - placebo</description>
    <arm_group_label>Placebo - 100 mg</arm_group_label>
    <arm_group_label>Placebo - 25 mg</arm_group_label>
    <arm_group_label>Placebo - 50 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 40-80 years of age (inclusive) when signing the Informed Consent.&#xD;
&#xD;
          2. Diagnosis of IPF or likely IPF per 2018 American Thoracic Society and European&#xD;
             Respiratory Society (ATS/ERS) criteria:&#xD;
&#xD;
               -  Study Investigator will confirm IPF diagnosis based on Interstitial Lung Disease&#xD;
                  (ILD) in consultation with relevant experts through a review of the subject's&#xD;
                  history, high-resolution computerized tomography (HRCT) scan, and lung biopsy (if&#xD;
                  applicable).&#xD;
&#xD;
               -  A lung biopsy is not required in the setting of a compatible clinical history and&#xD;
                  usual interstitial pneumonia (UIP) or probable UIP per HRCT.&#xD;
&#xD;
               -  Study Investigators will verify that a diagnosis of IPF and an HRCT were obtained&#xD;
                  within 7 years prior to signing the ICF.&#xD;
&#xD;
          3. Continued SOC IPF therapy (consisting of pirfenidone [Esbriet®] OR nintedanib [Ofev®]&#xD;
             OR neither) is acceptable, provided stable dosing of the drug for at least 8&#xD;
             consecutive weeks immediately prior to signing the ICF.&#xD;
&#xD;
          4. The effect of ORIN1001 on the developing human fetus, if any, is unknown. Therefore,&#xD;
             for the duration of study participation:&#xD;
&#xD;
               -  Women who are postmenopausal for &lt; 1 year before the Screening and not otherwise&#xD;
                  sterile (e.g., due to a surgical procedure) may be considered of child-bearing&#xD;
                  potential and require a negative pregnancy test prior to study registration. They&#xD;
                  must agree to (a) use effective contraception (i.e., hormonal or barrier method&#xD;
                  of birth control when engaged in heterosexual intercourse) or (b) abstinence&#xD;
                  throughout the study period AND for 4 weeks after final dosing with the IMP.&#xD;
&#xD;
               -  Men who are not otherwise sterile (e.g., due to a surgical procedure) must agree&#xD;
                  not to donate sperm and use effective contraception (i.e.,hormonal or barrier&#xD;
                  method of birth control when engaged in heterosexual intercourse) or abstinence&#xD;
                  throughout the study period AND for at least 16 weeks (due to the sperm life&#xD;
                  cycle) after final dosing with the IMP.&#xD;
&#xD;
          5. Written informed consent must be given prior to any study-related procedure that is&#xD;
             not part of standard medical care, understanding that the subject may withdraw it at&#xD;
             any time without prejudice to future treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Screening lab values that fail to meet the following criteria will render the subject&#xD;
             ineligible for study participation:&#xD;
&#xD;
               -  Platelet count &lt;100 × 109/L. Repeat measurements may be performed, but&#xD;
                  transfusion, in order to meet eligibility criteria, is not allowed.&#xD;
&#xD;
               -  Hemoglobin &lt;12.9 g/dL (men) and &lt;11.9 g/dL (women).&#xD;
&#xD;
               -  Prothrombin time (PT) or partial thromboplastin time (PTT) &gt;1.5 × upper limit of&#xD;
                  normal; international normalized ratio (INR) &gt;2.&#xD;
&#xD;
               -  Aspartate aminotransferase [AST] or alanine aminotransferase [ALT] &gt;1.5 × upper&#xD;
                  limit of normal (ULN).&#xD;
&#xD;
               -  Serum glutamic-oxaloacetic transaminase [SGOT] or serum glutamic pyruvic&#xD;
                  transaminase [SGPT]) &gt;2.0 × ULN.&#xD;
&#xD;
               -  Kidney disease with estimated glomerular filtration rate &lt;60 mL/min).&#xD;
&#xD;
          2. Forced vital capacity (FVC) ≤40% of predicted normal per site pulmonary function lab&#xD;
             protocol.&#xD;
&#xD;
          3. Diffusing capacity of the lungs for carbon monoxide (DLCO) ≤30% of predicted normal as&#xD;
             calculated according to the site pulmonary function lab protocol.&#xD;
&#xD;
          4. Forced expiratory volume in one second/forced vital capacity (FEV1/FVC) ratio &lt; 0.7.&#xD;
&#xD;
          5. Documented IPF exacerbation within 3 months of signing the ICF (e.g., &gt;5% or 10%&#xD;
             change in FVC and DLCO, respectively).&#xD;
&#xD;
          6. Listing for lung transplantation, defined as the assignment of a lung allocation score&#xD;
             or acceptance on the waiting list for lung transplantation.&#xD;
&#xD;
          7. Current and/or uncontrolled cardiovascular condition (e.g., clinically significant&#xD;
             arrhythmia or hypertension), &gt;Class II heart failure per New York Heart Association&#xD;
             criteria, unstable angina, myocardial infarction, coronary syndrome) within 6 months&#xD;
             of Screening which, as judged by the Investigator, might put the subject at risk&#xD;
             because of participation in the study.&#xD;
&#xD;
          8. Known cirrhotic liver, chronic liver, or biliary disease (with the exception of&#xD;
             Gilbert's syndrome or asymptomatic gallstones). Liver cirrhosis with portal&#xD;
             hypertension and active liver infection are exclusionary (note: cured hepatitis C is&#xD;
             not considered active).&#xD;
&#xD;
          9. Gastrointestinal disease (e.g., active bleeding or ulcers) or procedure that could&#xD;
             interfere with oral absorption or tolerance of the IMP, including difficulty&#xD;
             swallowing.&#xD;
&#xD;
         10. Diarrhea &gt;Grade 1 (i.e., increase of &gt;4 stools per day OR &gt;1 watery stool per day OR&#xD;
             moderate increase in ostomy output compared to baseline) will render a subject&#xD;
             ineligible for participation in this study. Anti-diarrheal medication (e.g.,&#xD;
             loperamide, sold under the brand name Imodium®, among others) is allowed.&#xD;
&#xD;
         11. Active malignancy within the past 12 months or ongoing active cancer treatment&#xD;
             (surgery, radiotherapy, chemotherapy or immunotherapy), except for adequately treated&#xD;
             Stage 1 cancer, nonmelanoma skin cancer, or in situ cervical cancer. Cancer in&#xD;
             complete remission or requiring only maintenance therapy (e.g., tamoxifen for breast&#xD;
             cancer) is not considered active.&#xD;
&#xD;
         12. Known bleeding risk due to platelet dysfunction, or inherited or acquired clotting&#xD;
             factor deficiency (e.g., von Willebrand disease, hemophilia).&#xD;
&#xD;
         13. Major trauma or surgery including but not limited to operations involving a major&#xD;
             organ (e.g., the cranium, chest, abdomen, or pelvic cavity) OR requiring a lengthy&#xD;
             recovery period (e.g., arthroplasty) within 3 months of signing the ICF; or expected&#xD;
             surgery during the trial period.&#xD;
&#xD;
         14. Central nervous system hemorrhagic event within 12 months of signing ICF; brain&#xD;
             arterio-venous malformation (AVM) or moderate-to-severe ischemic stroke within 6&#xD;
             months of signing ICF.&#xD;
&#xD;
         15. Concurrent use of full-dose therapeutic anti-coagulation (e.g., vitamin K antagonist,&#xD;
             dabigatran, hirudin, direct factor Xa inhibitors) or high dose anti-platelet therapy.&#xD;
             Aspirin &lt;81 mg/day, prophylactic subcutaneous (SC) heparin or SC low-molecular weight&#xD;
             heparin for deep vein thrombosis prophylaxis or heparin flush to maintain intravenous&#xD;
             catheter patency are allowed.&#xD;
&#xD;
         16. Long-term use of nonsteroidal anti-inflammatory agents, defined as &gt;4 days per week.&#xD;
&#xD;
         17. Receipt of hematopoietic growth factors, blood or blood product transfusion within 1&#xD;
             week of the first dose of IMP.&#xD;
&#xD;
         18. Disqualifying treatments within 60 days or 5 half-lives (whichever is longer) from&#xD;
             Randomization include:&#xD;
&#xD;
               -  Systemic corticosteroids (&gt;10 mg prednisone or equivalent).&#xD;
&#xD;
               -  Systemic immunosuppressive therapy.&#xD;
&#xD;
               -  Investigational agent other than study IMP.&#xD;
&#xD;
         19. Recreational drug use (including amphetamines, cocaine, barbiturates, opiates,&#xD;
             benzodiazepines, phencyclidine, and cannabinoids) for the duration of study&#xD;
             participation.&#xD;
&#xD;
         20. Clinically significant laboratory abnormality, medical or psychological comorbidity,&#xD;
             or concurrent medication that could compromise subject safety, data integrity or&#xD;
             requirements for study participation, per site Investigator in consultation with the&#xD;
             Sponsor.&#xD;
&#xD;
         21. Inability to attend in-person appointments per current clinical site COVID-19&#xD;
             guidelines and restrictions.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank Averill, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sleep, Allergy and Lung Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>YaLi Lee, MPH</last_name>
    <phone>510-219-6729</phone>
    <email>leeyali@fosunpharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stephanie Greene, PhD</last_name>
    <phone>805-231-8108</phone>
    <email>sgreene@orinove.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Respire Research</name>
      <address>
        <city>Palm Springs</city>
        <state>California</state>
        <zip>92262</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Mallett, RN</last_name>
      <email>a.mallett@respireresearch.com</email>
    </contact>
    <investigator>
      <last_name>Hassan Benchgroun, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Francis Sleep, Allergy &amp; Lung Institute</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amber Dunn, RN</last_name>
      <phone>727-210-4606</phone>
      <email>adunn@stfrancismed.com</email>
    </contact>
    <investigator>
      <last_name>Frank Averill, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Hospital</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Studies Unit</last_name>
      <phone>904-953-2255</phone>
    </contact>
    <investigator>
      <last_name>Tarik Haddad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Avanza Medical Research</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Hiller, RN</last_name>
      <email>a.hiller@avanzaresearch.com</email>
    </contact>
    <investigator>
      <last_name>Luis Murillo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Coastal Pulmonary and Critical Care</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karissa Dyar-Short, RN</last_name>
      <phone>727-822-6661</phone>
      <email>karissa.dyar@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Kelly Paradis, RN</last_name>
      <phone>727-822-6661</phone>
      <email>kaparadis12@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Warren Abel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Daniel Dilling, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Infinity Medical Research</name>
      <address>
        <city>North Dartmouth</city>
        <state>Massachusetts</state>
        <zip>02747</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leora Fernandes, RN</last_name>
      <phone>508-998-3041</phone>
      <email>LFernandes@infinitymedicalresearch.com</email>
    </contact>
    <contact_backup>
      <last_name>Michelle Ketchum, RN</last_name>
      <phone>508-998-3041</phone>
      <email>mketchum@infinitymedicalresearch.com</email>
    </contact_backup>
    <investigator>
      <last_name>Curtis Mello, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hannibal Clinic</name>
      <address>
        <city>Hannibal</city>
        <state>Missouri</state>
        <zip>63401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Laks, RN-BSN</last_name>
      <phone>573-231-3261</phone>
      <email>rachel.laks@hannibalregional.org</email>
    </contact>
    <contact_backup>
      <last_name>Rebekah Peiter, RN</last_name>
      <phone>573-231-3261</phone>
      <email>rebekah.peiter@hannibalclinic.com</email>
    </contact_backup>
    <investigator>
      <last_name>Humam Farah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03766</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haley Johnson, RN</last_name>
      <phone>603-653-0463</phone>
      <email>Haley.J.Johnson@hitchcock.org</email>
    </contact>
    <investigator>
      <last_name>Richard Enelow, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45220</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Sellers, RN</last_name>
      <phone>513-558-2148</phone>
      <email>mcmahasn@ucmail.uc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Elizabeth Hotel, RN</last_name>
      <email>hotelbh@ucmail.uc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Nishant Gupta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 11, 2020</study_first_submitted>
  <study_first_submitted_qc>November 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 25, 2020</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

